Roivant Sciences Ltd. and Priovant Therapeutics have reported positive Phase 3 results for brepocitinib in non-infectious uveitis, demonstrating substantial reductions in treatment failure and improved steroid-free disease control across two pivotal clinical trials. The investigational once-daily treatment met the primary and all key secondary endpoints in CLARITY-1 and CLARITY-2, with 62% of treated patients achieving steroid-free disease inactivity at Week 48 compared with 20% receiving placebo. The results could establish a new treatment option for patients with potentially sight-threatening eye inflammation, with Priovant preparing a supplemental regulatory submission during the first half of 2027.
The findings are particularly significant because the clinical benefits persisted despite a mandatory withdrawal of oral corticosteroids, which are commonly used to control uveitis but carry substantial risks during prolonged treatment. Brepocitinib is already approved in the United States for adult dermatomyositis under the brand name LISRAYA, although its use in non-infectious uveitis remains investigational.
How did brepocitinib reduce treatment failure in the CLARITY-1 and CLARITY-2 Phase 3 trials?
The CLARITY program enrolled 371 patients across two identically designed, randomized, double-masked, placebo-controlled Phase 3 studies. Participants received either brepocitinib 45 mg once daily or placebo for 48 weeks, allowing investigators to assess the treatment’s ability to maintain disease control following corticosteroid withdrawal.
All participants initially received oral corticosteroids at 60 mg daily for two weeks, followed by a mandatory six-week taper to zero. The primary endpoint measured time to treatment failure between Weeks 6 and 48, reflecting the recurrence or worsening of inflammatory disease activity after treatment initiation.
In CLARITY-1, involving 166 patients in the reported efficacy analysis, brepocitinib achieved a hazard ratio for treatment failure of 0.27 compared with placebo, with a 95% confidence interval of 0.17 to 0.43. CLARITY-2, involving 204 patients in the efficacy analysis, produced a hazard ratio of 0.22, with a confidence interval of 0.14 to 0.34. Both trials demonstrated statistical significance with p-values below 0.0001.
These hazard ratios indicate an approximately 73% and 78% lower relative hazard of treatment failure, respectively, during the observation period. They should not be confused with absolute reductions in the proportion of patients experiencing treatment failure, which were measured separately.
At Week 48, the cumulative incidence of treatment failure reached 35.4% among brepocitinib recipients in CLARITY-1, compared with 78.7% receiving placebo. The corresponding figures in CLARITY-2 were 32.4% and 77.8%, demonstrating consistent separation between treatment groups across both studies.
Median time to treatment failure exceeded 48 weeks among patients receiving brepocitinib, compared with approximately 12 weeks among placebo recipients. Because the treated groups had not reached median treatment failure during the observation period, the findings establish prolonged disease control through the trial rather than a precise median duration beyond 48 weeks.
Why could steroid-free uveitis control represent an important treatment advance?
Non-infectious uveitis involves inflammation affecting structures within the eye and can cause pain, floaters, blurred vision and potentially permanent visual impairment. The condition may occur independently or alongside systemic inflammatory disorders, including sarcoidosis and other autoimmune diseases.
Corticosteroids are frequently used to suppress acute ocular inflammation, but prolonged systemic exposure can produce significant complications. These include increased infection risk, elevated blood glucose, hypertension, osteoporosis and other adverse effects that limit their suitability for extended treatment.
The CLARITY trials specifically evaluated whether brepocitinib could maintain control of inflammation after oral corticosteroids were discontinued. This design makes sustained steroid-free disease inactivity an especially meaningful outcome for patients requiring long-term treatment.
Across both trials, 62% of patients receiving brepocitinib achieved steroid-free quiescence in both eyes at Week 48, compared with approximately 20% receiving placebo. The difference was statistically significant, with a p-value below 0.0001.
In CLARITY-1, steroid-free quiescence was achieved by 58.8% of brepocitinib recipients compared with 19.8% of placebo recipients. CLARITY-2 reported corresponding rates of 64.4% and 19.4%, providing consistent evidence across independently conducted studies.
Importantly, patients underwent a relatively rapid corticosteroid taper, leaving approximately 40 weeks of observation without oral steroid treatment. This extended steroid-free period strengthens the clinical relevance of the findings because disease recurrence frequently becomes a concern when immunosuppressive treatment is reduced.
Quan Dong Nguyen, professor of ophthalmology at Stanford University School of Medicine, indicated that the consistency of disease control despite rapid prednisone withdrawal could represent an important advance for patients requiring systemic treatment. He also highlighted the breadth of improvements observed across inflammatory activity, macular edema and visual functioning.
Did brepocitinib improve macular edema and vision-related outcomes in uveitis patients?
Beyond preventing treatment failure, brepocitinib demonstrated statistically significant benefits in ocular inflammation and structural complications that can contribute to visual impairment.
Macular edema occurs when fluid accumulates in the central retinal region responsible for detailed vision. It represents an important complication of uveitis because persistent swelling can impair reading, driving and other activities requiring sharp central vision.
Among patients entering the CLARITY program with macular edema, 42% of affected eyes in the brepocitinib groups experienced resolution by Week 48, compared with 4.8% in the placebo groups.
Individual trial findings were similarly favorable. CLARITY-1 reported macular edema resolution in 40.4% of eligible eyes receiving brepocitinib compared with 2.1% receiving placebo, while CLARITY-2 reported rates of 42.6% and 7.0%, respectively.
The treatment also reduced chorioretinal vascular leakage, which provides an objective indication of inflammatory activity affecting blood vessels within the eye. In CLARITY-1, 39.4% of eligible treated eyes achieved at least a 30% reduction in fluorescein angiography scores compared with 8.6% of placebo-treated eyes. CLARITY-2 demonstrated corresponding response rates of 54.9% and 7.2%.
Patient-reported visual functioning improved as well. Among participants eligible for assessment, 36.4% of brepocitinib recipients in CLARITY-1 achieved an improvement of at least five points on the National Eye Institute Visual Function Questionnaire composite score, compared with 13.7% receiving placebo.
CLARITY-2 reported corresponding improvements in 40.4% and 14.1% of participants. These findings suggest that the observed reductions in ocular inflammation were accompanied by measurable improvements in patients’ perceptions of their visual capabilities.
However, the questionnaire results do not establish equivalent improvements in every objective measure of visual acuity. Detailed analyses will be important for understanding how the treatment affects different dimensions of vision and everyday functioning.
How does brepocitinib’s TYK2 and JAK1 mechanism support treatment of ocular inflammation?
Brepocitinib is an oral inhibitor of tyrosine kinase 2 and Janus kinase 1, two intracellular enzymes involved in signaling pathways that regulate immune and inflammatory responses.
These pathways participate in the activity of multiple cytokines, making them relevant targets in autoimmune and inflammatory diseases. By inhibiting TYK2 and JAK1, brepocitinib is designed to reduce inflammatory signaling through a broader mechanism than treatments targeting a single cytokine.
This approach may be particularly relevant in non-infectious uveitis, where several immune pathways can contribute to persistent ocular inflammation. The positive findings across different uveitis subtypes support further investigation of the treatment’s potential applicability.
The companies reported consistent reductions in treatment failure among patients with intermediate uveitis, posterior uveitis and panuveitis. Benefits were also observed across groups with different previous exposure to tumor necrosis factor inhibitors and among patients with underlying conditions including birdshot chorioretinopathy and sarcoidosis.
Although these subgroup findings are encouraging, their interpretation must account for differences in patient numbers and disease characteristics. They do not independently establish equivalent effectiveness in every form of uveitis or every underlying inflammatory condition.
Brepocitinib’s existing approval for dermatomyositis provides additional clinical experience with its mechanism, but the risks and benefits of treatment must still be evaluated for the distinct population affected by non-infectious uveitis.
What did the CLARITY Phase 3 studies reveal about brepocitinib safety and tolerability?
Roivant Sciences and Priovant Therapeutics reported that brepocitinib was generally well tolerated during the 48-week treatment period, with most adverse events classified as mild or moderate.
Approximately 3% of participants discontinued treatment because of adverse events. The companies indicated that the observed safety profile was consistent with previous brepocitinib clinical experience, with no new safety signals identified.
These findings are encouraging for patients who may require prolonged systemic therapy. Nevertheless, the absence of newly identified safety signals does not mean the treatment is free of clinically important risks.
Brepocitinib belongs to a class of therapies that influence immune signaling through Janus kinase pathways. Its existing prescribing information for dermatomyositis includes important safety warnings, including a boxed warning, requiring careful consideration of treatment-related risks.
Because systemic immunomodulation may affect infection susceptibility and other health outcomes, physicians will need to assess the safety profile in the context of each patient’s medical history and concomitant treatments.
The top-line announcement did not provide a comprehensive adverse-event table or detailed exposure-adjusted incidence rates for every safety outcome. More extensive analyses will therefore be important for evaluating uncommon complications, longer-term tolerability and the benefit-risk balance of treatment in patients with uveitis.
What comes next for brepocitinib as Priovant prepares its 2027 FDA submission?
Priovant Therapeutics intends to submit a supplemental New Drug Application to the U.S. Food and Drug Administration during the first half of 2027, seeking to expand brepocitinib’s approved indications to include non-infectious uveitis.
The planned submission will build on the existing approval of LISRAYA for adults with dermatomyositis, which provides an established regulatory foundation for the same active ingredient. However, the FDA must independently determine whether the CLARITY evidence supports an acceptable benefit-risk profile for the proposed ophthalmic indication.
The results provide a substantial clinical foundation because two pivotal studies independently met their primary and all key secondary endpoints. The consistency of treatment effects across disease control, corticosteroid withdrawal, macular edema and patient-reported functioning represents an important strength of the development program.
Ben Zimmer, chief executive officer of Priovant Therapeutics, indicated that the company views non-infectious uveitis as a potential additional indication within its rare-disease immunology portfolio. Brepocitinib is also being investigated in cutaneous sarcoidosis and lichen planopilaris, although these additional uses remain unapproved.
For patients with non-infectious uveitis, the most significant finding is the possibility of maintaining long-term inflammatory control without continued systemic corticosteroid exposure. The magnitude and consistency of the Phase 3 results make brepocitinib a potentially important addition to the treatment landscape.
Nevertheless, cross-trial comparisons with existing treatments cannot establish superiority without appropriately designed comparative studies. Regulatory review, detailed safety evaluation and additional clinical analyses will determine whether brepocitinib can translate its positive pivotal findings into a new approved treatment option for this potentially sight-threatening condition.
